Doripenem: Position in clinical practice

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 5, 2009, Pages 507-514

  Dedhia, Harakh V ^a   McKnight, Richard ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

Author keywords

Doribax ; Doripenem; New antibiotic; Nosocomial pneumonia; Quinolone; VAP treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CLINDAMYCIN; DORIPENEM; ERTAPENEM; FROPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2A; PIPERACILLIN PLUS TAZOBACTAM; PROBENECID; PZ 601; SMP 216601; SMP 601; SULTAMICILLIN; TOMOPENEM; UNCLASSIFIED DRUG; VALPROIC ACID; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHLEBITIS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SUPERINFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING; BACTERIAL INFECTION; CROSS INFECTION; DRUG EFFECT; DRUG INTERACTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; MICROBIOLOGICAL EXAMINATION; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CARBAPENEMS; CROSS INFECTION; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS INFECTIONS;

EID: 68249138828     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.37     Document Type: Review

References (40)

1. Doripenem. Package insert, Johnson & Johnson, Raritan, NJ, USA.
2. Chastre, J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 36, 1089-1096 (2008). •• Evaluating the efficacy of doripenem for nosocomial and ventilator-associated pneumonia.
3. Jones RN, Huynh HK, Biedenbach DJ. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 54(1), 144-154 (2004).
4. Mikamo H, Izumi K, Hua YX et al. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynecological pathogens. J. Antimcrob. Chemother. 46(3), 471-474 (2000). (Pubitemid 30706054)
5. Merchant S, Gast C, Nathwani D et al. hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin. Ther. 30(4), 717-733 (2008). (Pubitemid 351680488)
6. Safdar N, Dezfulian C, Collard HR et al. Clinical and economic consequences of ventilator-assosciated pneumonia: a systematic review. Crit.. Care Med. 33(10), 2184-2193 (2005). • First paper suggesting the economical impact of using doripenem in intensive-care units. (Pubitemid 41437469)
7. Rello J, Ollendor DA, Oster G et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 122(5), 2115-2121 (2002). (Pubitemid 36051151)
8. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial phamacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy 26(9), 1320-1332 (2006).
9. Evangelista AT, Yee C, Pillar CM et al. Surveillance profiling of doripenem activity against Pseudomonas aeruginosa isolated from inpatients and ICU patients: results of the TRUST surveillance initiative. Presented at: The 45th Annual Meeting of the Infectious Diseases Society (IDSA). CA, USA, 4-7 October 2007.
10. Jones ME, Draghi DC, Brown NP et al. Baseline surveillance profile of doripenem (DOR) against key Gram-negative pathogens encountered in the United States. Presented at: The 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 27-30 September 2006.
11. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. 59(4), 220-228 (2006). (Pubitemid 43854733)
12. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48(8), 3086-3092 (2004). (Pubitemid 38989178)
13. Davies TA, Shang W, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52, 1510-1512 (2008).
14. Kim A, Banevicius MA, Nicolau DP et al. In vivo pharmacodynamic profiling of doripenem human simulated exposures against Pseudomonas aeruginosa. Am. Soc. Microbiol. (2008) (In Press). (Pubitemid 351915681)
15. Aransas-Torres M, Pillar C, Shah D, Sahm D. Stratified analysis of doripenem activity against enterobacteriacae and Psuedomonas aeruginosa according to patient location: inpatients and ICU patients. Presented at: 47th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, 17-20 September (2007).
16. Pillar C, Torres MK, Brown N, Shah D, Sahm D. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother. 52(12), 388-4399 (2008).
17. Bhavnani SM, Hammel JP, Cirincione BB et al. Use of pharmacokinetic- pharmacodynamic target attainment analyses to support Phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 49(39), 44-3947 (2005).
18. Anderson DL. Doripenem. Drugs Today 42(6), 399-404 (2006).
19. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn. Microb. Infect. Dis. 52, 71-74 (2005).
20. Viaene E, Chanteux H, Servais H et al. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46(8), 2327-2332 (2002). (Pubitemid 34793431)
21. Tanimoto K, Tomita H, Fujimoto S et al. Fluroquinolone enhances the mutation frequency of meropenem selected carbapenem resistance in Pseudomonas aeruginosa, but use of high potency drug doripenem inhibits mutant formation. Antimicrob. Agents Chemother. 52(10), 3795-3800 (2008).
22. Mushtaq S, Ge Y, Livermore DM. In vitro-activity against characterized isolates, mutants and transconjugates and resistance selection potential. Antimicrob. Agents Chemother. 48(4), 3086-3092 (2004).
23. Tsuji M, Ishii Y, Ohno A, Miyazaki S et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42(1), 94-99 (1998). (Pubitemid 28053333)
24. Psathas P, Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin. Ther. 30(11), 2075-2087 (2008).
25. Brammer MK, Chan P, Heatherley K. Compatibility of doripenem with other drugs during simulated Y-site administration. Am J. Health System Pharm. 65(13) 1261-1265 (2008). (Pubitemid 351898361)
26. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J. Antimicrob. Chemother. 55, 944-949 (2005).
27. Nicolau DP. Pharmacodynamic optimization of β-lactams in the patient care setting. Crit.Care 12(Suppl. 4), 1-5 (2008).
28. Owens RC Jr. An overview of harms associated with β-lactam antimicrobials: where do the carbapenems fit in? Crit. Care 12(4 Suppl. 3), 1-11 (2008).
29. Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit. Care 12(Suppl. 4), 1-7 (2008).
30. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222, 114-124 (2006). (Pubitemid 44275125)
31. Lucasti C, Jasovich A, Umeh O et al. Treatment of complicated intra-abdominal infections: doripenem versus meropenem. Presented at: The 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 27-30 September 2006.
32. Solomkin JS, Umeh O, Jiang J et al. Doripenem versus meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections. Presented at: The 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 27-30 September 2006.
33. Malafia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections. Presented at: The 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). CA, USA, 27-30 September 2006.
34. Kaniga K, Redman R, Llorens L, Friedland I. Prevalence of ESBLs and flouroquinolone resistant isolates form Phase 3 trials of complicated urinary tract infections including pyelonephritis. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, 17-20 September 2007.
35. Naber K, Redman R, Kotey P, Llorens L, Kaniga K. Intravenous therapy with doripenem versus levofloxacin with an option to oral step-down therapy in the treatment of complicated urinary tract infection and pyelonephritis. Presented at: The European Society of Clinical Microbiology and Infectious Diseases. Munich, Germany, 31 March - 3 April 2007.
36. Goldstein E, Citron D, Merriam CV, Warren Y, Tyrrell K, Fernandez H. In vitro activity of doripenem against aerobic and anerobic bacteria isolated from infected diabetic foot wounds. Presented at: The 47th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA, 17-20 September 2007.
37. MacGowan AP, Bowker KE, Noel AR. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agent Chemother. 52(4), 1401-1406 (2008).
38. Clinicaltrials.gov www.clinicaltrials.gov (Accessed 17 July 2008)
39. European Medical Agency www.emea.europa.eu (Accessed 17 July 2008)
40. Doribax: doripenem for injection www.doribax.com (Accessed 17 July 2008)